The analysis showed that after three years treatment with CellCept + tacrolimus, kidney survival was 85.9% versus 80.3% with patients taking sirolimus + tacrolimus immunosuppressants. The outcome was even better for higher risk patients with a kidney survival rate of 74.5% vs 57.5%[i]. The new data were presented at the European Society for Organ Transplantation (ESOT), Geneva, Switzerland. Previous data have shown that CellCept gives a survival benefit when compared to older immunosuppressant drugs and now these new data demonstrate the survival benefit of CellCept combinations over the newer drug regimens.
Kidneys are the most commonly transplanted organs[ii]; for every kidney available there are four people waiting to receive one[iii]. After transplantation, people need to take a combination of immunosuppressant drugs for the rest of their lives to prevent the body rejecting the new organ. By preserving the transplanted organ with CellCept based combinations, doctors can help patients to keep their organs longer, thereby, reducing the burden on the already limited donor pool. One way to achieve this is by choosing combinations based on the low toxicity profile of CellCept, along with reduced doses of the more toxic immunosuppressant drugs to decrease the risk of losing the new kidney.
"We have learnt that the combination of cyclosporine/sirolimus is toxic to the kidney over time and as a result some doctors have switched to a sirolimus/tacrolimus combination, that was perceived to be less toxic," said Prof Herwig-Ulf Meier Kriesche, University of Florida, Gainesville, Fl, USA. "Now we have the data to show that this combination is just as damaging. These data, along with this latest analysis of patients on CellCept combinations, should help us make an evidence-based choice on how best to reduce the risk of toxicity, which we know is associated with some long-term immunosuppressant regimens," he added.
Page: 1 Related medicine news :1
Contact: Helen Swift
. Leading prevention researchers meeting in Washington, D.C., May 30-June 1, 20072
. Leading advocates express support for microbicide research, despite disappointing trial results3
. Leading European experts in magnetic resonance for animals4
. Leading healthcare authorities to address safety and effectiveness5
. Leading international osteoporosis experts to present at worlds largest osteoporosis congress6
. Leading hepatology textbook edited by SLU researchers7
. Leading groups offer NIH direct links to journals to make research access easy for public8
. Leading pediatricians group recommends infants sleep in cribs, not parents beds9
. Leading genomic technology expert to present Dickson Prize Lecture at Pitt10
. Leading experts discuss how to protect premature infants against RSV, a potentially dangerous virus11
. Leading sleep expert at Wake Forest to speak at NIH Consensus Conference